Abbott
OrganizationHeard in 34 episodes across 14 shows since Oct 2025
A multinational healthcare company that develops and manufactures medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals.
Episodes
This week
Expert statements
Share of the conversation
Mentions of Abbott per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Sep 12 | 0.01‰ | 1 |
| Sep 14 | 0.02‰ | 1 |
| Sep 23 | 0.01‰ | 1 |
| Oct 11 | 0.01‰ | 1 |
| Oct 17 | 0.02‰ | 1 |
| Oct 21 | 0.06‰ | 6 |
| Oct 23 | 0.07‰ | 1 |
| Nov 3 | 0.01‰ | 1 |
| Nov 9 | 0.02‰ | 1 |
| Nov 18 | 0.01‰ | 1 |
Email alert
Email me when Abbott comes up on a podcast
One email a week at most, with the new episodes that mention Abbott. Free, no account needed, unsubscribe in one click.
What experts have said about Abbott
10 statements · 5 positive · 5 negative
Abbott’s nutrition segment is the weak part of its portfolio
“they're finally spinning off their nutrition segment because that's probably the black sheep of the overall portfolio for them”
Open the episode · SpaceX, Tesla Boards Study Possible $3.5 Trillion MergerListen at 10:09
Spinning off nutrition allows Abbott to focus on medical devices
“that allows them to focus on their kind of key growth drivers, which is in the medical device space”
Open the episode · SpaceX, Tesla Boards Study Possible $3.5 Trillion MergerListen at 10:18
ACA or Medicaid cuts could reduce Abbott procedure volumes and revenue
“ACA cuts, Medicaid cuts, that could hurt some of their procedure volumes, which then would hurt revenue”
Open the episode · SpaceX, Tesla Boards Study Possible $3.5 Trillion MergerListen at 13:09
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
34 episodes featuring Abbott, newest first
- Nov 18, 2026
Nvidia rally fades as Target and cybersecurity stocks stand outStock Market Today With IBDNov 18, 2026 - Nov 9, 2026
AbbVie builds a risk-managed neuroscience portfolioBusiness Of BiotechNov 9, 2026 - Nov 3, 2026
Cramer weighs tech’s sell-off against healthcare’s growth caseMad Money w/ Jim CramerNov 3, 2026 - Oct 23, 2026
Lanifibranor faces a pivotal test in MASHBreaking BiotechOct 23, 2026 - Oct 21, 2026
Data centers revive towns while corporate power concentratesMarketplaceOct 21, 2026 - Oct 21, 2026
Netflix faces an engagement test as capital costs stay highBrew MarketsOct 21, 2026